Tier 2 — strong

Berberine improves negative symptoms and cognitive function in patients with chronic schizophrenia via anti-inflammatory effect: a randomized clinical trial

Pu Z, Wen H, Jiang H, Hou Q, Yan H
Chinese medicine 2023 18(1):41

Bibliography

PubMed
PMID 37069570
PubMed Central
PMC10108529
DOI
10.1186/s13020-023-00746-4
Funding
Indexed support: Key Subject funds of Tongxiang. See the publication for grant details.
Competing interests
The authors declared no competing interests in the publication.

Study snapshot

DesignRandomized controlled human trial
ModelHuman participants; see population
Sample106 analyzed per protocol; 56 versus 50
InterventionAdjunctive berberine versus placebo in chronic schizophrenia
Duration3 months
EndpointsMetabolic or symptom outcomes; Inflammatory markers; Tolerability

What the study showed, in plain terms

Negative-symptom, selected cognitive and inflammatory measures favored berberine in the reported analysis.

Key findings

  • Negative-symptom, selected cognitive and inflammatory measures favored berberine in the reported analysis.

What this study can and cannot tell us

Per-protocol analysis and multiple measures can bias results; no evidence for cognitive enhancement in healthy users.

Related papers in the corpus

Tier 2
Adjunctive berberine reduces antipsychotic-associated weight gain and metabolic syndrome in patients with schizophrenia: a randomized controlled trial
Chan M et al. · Psychiatry and clinical neurosciences · 2022
Tier 4
Berberine treatment for weight gain in patients with schizophrenia by regulating leptin rather than adiponectin
Qiu Y et al. · Asian journal of psychiatry · 2022
Tier 2
Improvement of adjunctive berberine treatment on negative symptoms in patients with schizophrenia
Li M et al. · European archives of psychiatry and clinical neuroscience · 2022
Tier 2
Effect of Berberine Hydrochloride on the Diversity of Intestinal Flora in Parkinson's Disease Patients
Li J et al. · Contrast media & molecular imaging · 2022
Tier 2
The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial
Li M et al. · Psychiatry research · 2021

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology